OBJECTIVE: Whether antepartum (AP) inpatient admissions for hypertensive diseases of pregnancy (HDP) are associated with increased risk for postpartum (PP) readmissions is not well characterized. The purpose of this study was to determine whether AP HDP admission is associated with 30-day PP HDP readmission rates. STUDY DESIGN: Delivery hospitalizations October and November of 2010 to 2014 were identified using the Nationwide Readmissions Database, a nationally representative discharge database. We identified AP admissions with the primary diagnosis of HDP occurring within 9 months preceding delivery and PP readmissions within 30 days of discharge from delivery. The primary outcome was 30-day HDP readmission. Risk for severe maternal morbidity (SMM) was also analyzed based on CDC criteria. AP admission length of stay of (aLOS) and number of antepartum admissions were also analyzed as risk factors for readmission. Adjusted log linear regression models were used to analyze risk for readmission and morbidity with risk ratios (RR) and 95% confidence intervals (CI) as the measures of effect. RESULTS: 3.1 million deliveries were analyzed with 11,393 (0.4%) antepartum admissions and 8,964 (0.3%) postpartum readmissions. Of the women admitted AP, 92% were admitted only once with median aLOS 1.6 days. AP admission was associated with higher risks of 30-day PP HDP readmission (2.4% vs. 0.3%, p<0.01). In adjusted analysis controlling for the presence of HDP at delivery, patients with an antepartum HDP admission were at 65% higher risk of 30-day postpartum readmission (RR 1.65, 95% CI 1.45, 1.87) ( Table 1) . Risk for SMM was not significantly increased. Patients who had more than one AP admission further increased risk for readmission. In comparison, aLOS > 7d was significantly associate with a 50% decreased risk for PP HDP readmission (RR¼0.50, 95% CI: 0.27, 0.92, p<0.01) ( Table 2) . CONCLUSION: AP HDP admission is a risk factor for readmission independent of HDP status at delivery. However, AP admission was not associated with SMM at readmission and increased aLOS was associated with decreased readmission risk. Longer surveillance of patients in the hospital may result in more detailed management plans that subsequently facilitate outpatient management. For patients with AP admissions close interval follow up after delivery discharge may be indicated. OBJECTIVE: Preeclampsia (PE) is a disease of incompletely understood etiology that is the leading contributor to iatrogenic preterm birth (PTB). Our objective was to identify if PE in dichorionic pregnancies is characterized by similarities or dissimilarities in the transcriptome profile of the two placentas. STUDY DESIGN: Total RNA was extracted from 60 placental villous tissue samples and subjected to RNA-seq using the Illumina platform. Our study was designed to include two analytical stages: In the first stage placental samples (n¼18) originated from singleton pregnancies with unambiguous clinical phenotypes: 1) severe features early-onset PE (sPE, n¼8, GA: 30AE1 wks); 2) idiopathic preterm birth (n¼5, GA: 32AE1wks) and 3) term non-labor (n¼5, GA: 39AE1wks). These samples were used to extract a generic transcriptomic signature of PE placenta. In the second stage placentas of 16 twin pregnancies classified based on chorionicity and PE diagnosis were included as follows: di-di nonPE (n¼7, GA: 32AE1 wks), mono-di nonPE (n¼2, GA: 32AE1 wks), di-di PE (n¼5, GA: 33AE2 wks) and mono-di PE (n¼2, GA: 33AE3 wks). Two separate biopsies were sequenced from monochorionic placentas. An additional set of singleton PE placentas (n¼10, GA: 33AE1 wks) was sequenced interspaced among the twin placentas to control for batch effects. Principal components analysis (PCA) and statistical modeling for similarity and dissimilarity between sibling placentas were applied. RESULTS: Our first stage analysis extracted a subset of 613 transcripts differentially expressed between sPE and non-PE singleton placentas. This molecular classifier showed linear separability among first stage samples independent of GA at birth. When applied to twin gestation placentas the classifier revealed several characteristics: 1) In the non-PE cases, biopsies from monochorionic placentas had more similar expression patterns of the genes composing the PE signature than dichorionic placentas which were more scattered in the PCA space (Fig. A) ; 2) Monochorionic nonPE placentas have closer proximity to the PE space compared to singleton nonPE placentas; 3) Dichorionic sibling placentas of pregnancies complicated by PE were the most discordant (Fig. B) . CONCLUSION: In dichorionic pregnancies complicated by PE, the disease affects each placenta individually. Conversely, PE in twins could be the result of a single diseased placenta. 2015 to June 2017. We included patients with chronic hypertension with superimposed preeclampsia ("cHTN+preSF") and those with preeclampsia with severe features ("preSF"). We abstracted clinical information, including maternal BMI and medication administration data from the electronic medical record system. We used Student's t-test and Chi-squared test to examine differences between the groups. We performed a two-way analysis of variance to examine the effect of maternal severe hypertension (cHTN+preSF vs preSF) and obesity (BMI !30) on the total amount of IV labetalol required during the antepartum admission. RESULTS: We identified 209 patients treated with IV labetalol, including 124 with preSF and 85 with cHTN+preSF. The average amount of labetalol required was 44.5mg for the preSF group and 72.0mg for the cHTN+preSF group (p<0.01). Mean BMI at delivery was 37.7 for preSF and 40.2 for cHTN+preSF(p¼0.04). Using a twoway analysis of variance, we modeled the total administration of IV labetalol as a function of maternal hypertension type and BMI:
Total IV labetalol (mg) ¼ 24 + 27 (if BMI !30) + 0 (if preSF) + 27 (if cHTN+preSF)
The findings were unchanged after controlling for maternal age, gravidity, and other antihypertensive medications used (Table 1) . CONCLUSION: We demonstrate that chronic hypertension and maternal obesity are independent factors that directly increase the total amount of IV labetalol required to control severe hypertension in preeclampsia. We additionally offer a simple tool for clinicians to anticipate dosing of IV labetalol in acute management of severe hypertension.
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